<DOC>
	<DOCNO>NCT00700544</DOCNO>
	<brief_summary>A multicenter randomize trial evaluate possible benefit androgen post remission therapy attempt improve outcome AML old patients.All patient receive ICL regimen induction randomize receive , achieve CR PR , maintenance therapy include androgen . Patients randomize androgen additionally receive 10 20 mg accord body weigh norethandrolone daily 2 year</brief_summary>
	<brief_title>Treatment Outcome Elderly Patients</brief_title>
	<detailed_description>- Induction Therapy : - Idarubicin , 8mg/m2 d1-5 ; Cytarabine , 100mg/m2 d1-7 Lomustine , 200mg/m d1 - CR PR : randomisation = maintenance therapy include androgen - Maintenance therapy : - 6 course reinduction idarubicin ( 8mg/m2 d1 ) cytarabine ( 100mg/m2d1-5 , subcutaneously ) every 3 month , , course , continuous regimen methotrexate 6-mercaptopurine . - Patients randomize androgen additionally receive 10 20 mg accord body weigh norethandrolone daily 2 year</detailed_description>
	<mesh_term>Norethandrolone</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>Patients age 60 year `` de novo '' AML accord FAB criterion AML 20 % myeloid marrow blast sign date informed consent OMS score &lt; 3 Life expectancy &gt; 1 month Patients age &lt; 60 year AML M3 classificated accord FAB criterion extramedular localisation AML OMS score ≥ 3 clinical Abnormal Cardiac fonction leave ejection fraction &lt; 40 % abnormal renal function creatinine clearance &lt; 50/ml/mn/m² abnormal hepatic function previous cerebral stroke previous malignancy : prostate , breast cancer ( male ) PSA dosage &gt; 4 Any coexist medical psychological condition would pleclude participation require study procedure</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>AML</keyword>
	<keyword>elderly patient</keyword>
	<keyword>Treatment outcome</keyword>
</DOC>